LTRN Valuation Metrics
FCF$-15.68M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Lantern Pharma Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Lantern Pharma Inc
Did you know?
Capital expenditures decreased by 86% from FY24 to FY25.
Current Price
$2.23
+5.19%Profile
Valuation (TTM)
Market Cap$24.94M
P/E-1.46
EV—
P/B3.82
Shares Out11.18M
P/Sales—
Revenue$0.00
EV/EBITDA—
Lantern Pharma Inc (LTRN) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →LTRN Valuation & Fair Value Analysis
Lantern Pharma Inc (LTRN) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -1.46. Price-to-book ratio is 3.82. PEG ratio is 0.04.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Lantern Pharma Inc's intrinsic value.